Products - Arthritis | Topic

Showing 21 products

Date | Sort by Title

Status: In developmentRemove ‘Status: In development’ filter

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 June 2021
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
14 July 2021
Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 July 2021
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 July 2021
Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
28 July 2021
Magnetic resonance therapy for knee osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
25 August 2021
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
15 September 2021
Tofacitinib for treating juvenile idiopathic arthritis [ID2718]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
20 October 2021
Osteoarthritis: care and management (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
19 October 2022
Osteoarthritis - naproxcinod [ID417]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Osteoarthritis - diacerein [ID332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Geniculate artery embolisation for pain from knee osteoarthritis
Status:
In development | In consultation
Programme:
Interventional procedures guidance
Consultation end date:
25 June 2021
Expected publication date:
TBC
Lateral elbow resurfacing for arthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Supercapsular Percutaneously Assisted Total Hip replacement for osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Sternoclavicular joint replacement for arthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Total hip arthroplasty using the superpath approach for osteoarthritis
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
TBC

Arthritis Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 21 products

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for moderate rheumatoid arthritis after conventional DMARDs have failed (partial review of TA375) [ID2710]

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]

Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)

Magnetic resonance therapy for knee osteoarthritis

Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

Tofacitinib for treating juvenile idiopathic arthritis [ID2718]

Osteoarthritis: care and management (update)

Osteoarthritis - naproxcinod [ID417]

Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]

Osteoarthritis - diacerein [ID332]

Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]

Geniculate artery embolisation for pain from knee osteoarthritis

Lateral elbow resurfacing for arthritis

Supercapsular Percutaneously Assisted Total Hip replacement for osteoarthritis

Sternoclavicular joint replacement for arthritis

Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]

Total hip arthroplasty using the superpath approach for osteoarthritis

Arthritis Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 21 products

Status
1 selected